(89 days)
PALMAZ™ Balloon-Expandable Stent
Not Found
No
The summary describes a mechanical device (a stent and delivery system) and its performance studies focus on mechanical properties and dimensional verification. There is no mention of AI or ML in the intended use, device description, or performance studies.
Yes
The device is intended for palliative treatment of biliary duct strictures caused by malignant tumors, which is a therapeutic purpose. It directly intervenes to maintain the patency of biliary ducts, aiming to alleviate symptoms and improve quality of life for patients.
No
The device is a stent system intended for palliative treatment of biliary duct strictures caused by malignant tumors, which is a therapeutic purpose, not a diagnostic one.
No
The device description clearly outlines physical components including a stent, delivery catheter, balloon, and radiopaque markers, indicating it is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to maintain patency of a biliary duct and for palliative treatment of biliary duct strictures. This is a therapeutic intervention performed directly on the patient's body.
- Device Description: The device is a stent system, which is an implantable medical device used to open and support a blocked or narrowed passage.
- Mechanism of Action: The device works by physically expanding and holding open the biliary duct.
- Lack of Diagnostic Purpose: The device is not used to diagnose a condition, measure a substance in a biological sample, or provide information about a patient's health status based on in vitro testing.
IVD devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. This device is used in vivo (within the living body) for treatment.
N/A
Intended Use / Indications for Use
The Peripheral AVE Biliary Stent System is intended for use in patients who are eligible for percutaneous transluminal angioplasty (PTA) to maintain patency of a biliary duct which is occluded by tumor.
The Peripheral AVE Bilairy Stent System is indicated for palliative treatment of biliary duct strictures caused by malignant tumors.
Product codes
78FGE
Device Description
The Peripheral AVE Bilairy Stent System consists of a balloon-expandable intraluminal stent premounted onto the balloon of an over-the-wire delivery catheter. The Peripheral AVE Bilairy Stent System has two radiopaque platinum markers imbedded in the inner shaft (at each end of the stent) to aid in the placement of the stent during fluoroscopy. The delivery system is compatible with 0.035" guidewires and has a useable length of 75 cm to 90 cm. The Peripheral AVE Bilairy Stent System is provided enclosed in a sterile package.
Size Range:
Diameters - 6.0 mm to 10.0 mm Lengths -- 17 mm to 60 mm
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
fluoroscopy
Anatomical Site
Biliary Ducts
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
- Peripheral AVE Biliary Stent System vs JJIS Palmaz™ Balloon-Expandable Stent - Balloon Performance Study
Purpose: To compare the minimum burst pressure and deflation times of the Peripheral AVE Biliary Stent System balloons to the PALMAZ™ Balloon-Expandable Stent balloons. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results: The test proved substantial equivalence. - Peripheral AVE Biliary Stent System vs JJIS Palmaz™ Balloon-Expandable Stent - Two Plane Crush Strength Study
Purpose: To determine and compare the radial strengths of the Peripheral AVE Biliary Stent and the PALMAZ™ Balloon-Expandable Stent by graphically representing the amount of force required to crush a stent to fifty percent (50%) of its deployed diameter. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results: The test proved substantial equivalence. - Peripheral AVE Biliary Stent Dimensional Verification and Stent Uniformity at Nominal Deployment
Purpose: To verify that processed Peripheral AVE Biliary Stents meet diameter and length specifications after deployment. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results: The results conclude that the stents tested meet the labeled specifications for stent diameter and stent length.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
PALMAZ™ Balloon-Expandable Stent
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
Image /page/0/Picture/1 description: The image shows the logo for Peripheral AVE. The logo consists of the word "Peripheral" in a simple, sans-serif font, followed by the letters "AVE" in a more stylized font. Below the text is a graphic element that resembles a stylized wave or swoosh, adding a dynamic visual element to the logo.
Peripheral AVE Biliary Stent System
510(k) Summary of Safety and Effectiveness
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: 4983008
GENERAL INFORMATION
Applicant:
| Date: | 27 August, 1998 |
|---|---|
| Name: | Peripheral AVE |
| Address: | 2330A Circadian Way |
| Santa Rosa, CA 95407 | |
| Contact: | Paul A. Meyer, P.E., RAC |
| Phone Number: | (707) 541-3254 |
| FAX Number: | (707) 543-5454 |
Trade Name:
| Device Name: | Peripheral AVE Biliary Stent System |
|---|---|
| Model Numbers: | TBD |
| Classification Name: | Catheter, Biliary and accessories |
Section 513 Device Classification:
| Classification | Class II |
|---|---|
| Classification Panel: | 78FGE |
000524
1
EQUIVALENCE
Peripheral AVE claims substantial equivalence to the Johnson & Johnson Interventional Systems' PALMAZ™ Balloon-Expandable Stent.
2
INTENDED USE
The Peripheral AVE Biliary Stent System is intended for use in patients who are eligible for percutaneous transluminal angioplasty (PTA) to maintain patency of a biliary duct which is occluded by tumor.
The Peripheral AVE Bilairy Stent System is indicated for palliative treatment of biliary duct strictures caused by malignant tumors.
3
DEVICE DESCRIPTION
The Peripheral AVE Bilairy Stent System consists of a balloon-expandable intraluminal stent premounted onto the balloon of an over-the-wire delivery catheter. The Peripheral AVE Bilairy Stent System has two radiopaque platinum markers imbedded in the inner shaft (at each end of the stent) to aid in the placement of the stent during fluoroscopy. The delivery system is compatible with 0.035" guidewires and has a useable length of 75 cm to 90 cm. The Peripheral AVE Bilairy Stent System is provided enclosed in a sterile package.
Size Range:
Diameters - 6.0 mm to 10.0 mm Lengths -- 17 mm to 60 mm
4
Comparison to Predicate Device:
Per 807.92(a)(6), the 510(k) summary contains a summary of the technological characteristics of your device compared to
the predicate device.
| Characteristic
Compared | AVE Bridge™ Stent System | PALMAZ™ Balloon-Expandable
Stent |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use: | The Peripheral AVE Biliary Stent
System is intended for use in patients
to maintain patency of a biliary duct
which is occluded by tumor.
The Peripheral AVE Biliary Stent
System is indicated for palliative
treatment of biliary duct strictures
caused by malignant tumors. | The device is a permanent implant
intended to maintain patency of a bile duct
which is obstructed by scar tissue or tumor. |
| Physical
Characteristics
(Stent): | 316L stainless steel balloon
expandable stent - premounted
Diameters - 6 mm to 10 mmLengths - 16 mm to 60 mm | 316L stainless steel balloon expandable
stent - premounted or unmounted
Diameters - 4 mm to 12 mmLengths - 9 mm to 40 mm |
| Physical
Characteristics
(Delivery catheter): | balloon delivery system - PTA catheter
5.3-5.8 F shaft size75 cm to 90 cm length0.035 in. Guidewire diameter | balloon delivery system - PTA catheter 5 F to 7 F shaft size75 cm length0.035 in. Guidewire diameter for unmounted stents - Medi-tech PE-MT™
PTA balloon catheters 5 F to 9 F shaft size60 cm to 120 cm length0.035 in. Guidewire diameter |
| Anatomical Sites: | Biliary Ducts | Biliary Ducts |
| Target Population: | Patients with biliary duct obstruction
caused by malignant tumor | Patients with biliary duct obstruction
caused by tumor or scar tissue |
5
Performance Testing:
Per 807.92(b)(1) If the determination of substantial equivalence is also based on an assessment of performance data, the summary includes a brief discussion of the non clinical tests and how their results support a determination of substantial equivalence
1. Peripheral AVE Biliary Stent System vs JJIS Palmaz™ Balloon-Expandable Stent - Balloon Performance Study
Purpose:
To compare the minimum burst pressure and deflation times of the Peripheral AVE Biliary Stent System balloons to the PALMAZ™ Balloon-Expandable Stent balloons. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results:
The test proved substantial equivalence.
2. Peripheral AVE Biliary Stent System vs JJIS Palmaz™ Balloon-Expandable Stent - Two Plane Crush Strength Study
Purpose:
To determine and compare the radial strengths of the Peripheral AVE Biliary Stent and the PALMAZ™ Balloon-Expandable Stent by graphically representing the amount of force required to crush a stent to fifty percent (50%) of its deployed diameter. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results:
The test proved substantial equivalence.
3. Peripheral AVE Biliary Stent Dimensional Verification and Stent Uniformity at Nominal Deployment
Purpose:
To verify that processed Peripheral AVE Biliary Stents meet diameter and length specifications after deployment. The data gathered will support a premarket notification for the Peripheral AVE Biliary Stent System.
Results:
The results conclude that the stents tested meet the labeled specifications for stent diameter and stent length.
6
CONCLUSIONS:
The Peripheral AVE Biliary Stent vs the JJIS Palmaz™ Balloon-Expandable Stent performance testing results prove that the Peripheral AVE Biliary Stent is substantially equivalent to the JJIS Palmaz™ Balloon-Expandable Stent
Additional Information:
Per 807.92(d), the summary includes any other information reasonably deemed necessary by FDA.
BIOCOMPATIBILITY
The materials employed in the Peripheral AVE Biliary Stent Delivery System passed all biocompatibility tests.
STERILIZATION INFORMATION
The Peripheral AVE Biliary Stent System is provided sterile.
The Peripheral AVE Biliary Stent System is not intended for sterilization or reuse/ resterilization by the user.
Validation
Peripheral AVE validates the sterilization method, for its stent delivery system products, quarterly each year according to the ANSI/ AAMI/ ISO 11137 - 1994, Method I. Sterilization of Healthcare Products - Requirements for Validation and Routine Control -Radiation Sterilization.
Sterility Assurance Level (SAL)
The Sterility Assurance Level or SAL for the validated AVE stent systems is 106.
Pyrogen Testing
The Peripheral AVE Biliary Stent System is labeled "pyrogen free". LAL testing is performed daily, in compliance with FDA guideline on Validation of Limulus Amebocyte Lysate Test as an End Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices - Section V - 2 Inhibition and Enhancement Testing, as part of Peripheral AVE's product release criteria.
7
Image /page/7/Picture/2 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three heads, representing the department's mission to protect the health of all Americans and provide essential human services. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The logo is simple and recognizable, and it is often used on official documents and websites related to the department.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV 25 1998
Mr. Paul A. Mever RA/QA/CA Manager Peripheral AVE 2330A Circadian Way Santa Rosa, California 95407
Re: K983008
Peripheral AVE Biliary Stent System Regulatory Class: II 21 CFR §876.5010 Product Code: 78 FGE Dated: August 27, 1998 Received: August 28, 1998
Dear Mr. Mever:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicte devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
8
Page 2 - Mr. Paul A. Meyer
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification if the limitation statement above is added to your labeling, as described.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Susan Alpert, Ph.D., M. Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
9
Page__________________________________________________________________________________________________________________________________________________________________________
510(k) Number (if known): K983008
Device Name:_ Peripheral AVE Biliary Stent System
FDA's Statement of the Indications For Use for device:
The Peripheral AVE Biliary Stent System is intended to maintain patency of biliary duct which is occluded by a malignant tumor.
ho'cau Yh
Division Sign Off
(Division Sign-Off) Division of Reproductive, Abdominal ENT, and Radiological Devi 510(k) Number
Prescription Use OR
(Per 21 CFR 801.109)
Over-The-Counter Use_